Daniel Lynch Sells 400 Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Stock

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Director Daniel Lynch sold 400 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $60.00, for a total value of $24,000.00. Following the completion of the sale, the director now directly owns 130,544 shares in the company, valued at $7,832,640. This trade represents a 0.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Daniel Lynch also recently made the following trade(s):

• On Monday, February 10th, Daniel Lynch sold 175,000 shares of SpringWorks Therapeutics stock. The stock was sold at an average price of $54.46, for a total transaction of $9,530,500.00.

SpringWorks Therapeutics Trading Up 7.5 %

NASDAQ SWTX opened at $59.93 on Friday. The business’s 50-day moving average price is $40.70 and its two-hundred day moving average price is $37.47. SpringWorks Therapeutics, Inc. has a 12 month low of $28.21 and a 12 month high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last announced its earnings results on Thursday, February 20th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative net margin of 203.09% and a negative return on equity of 48.21%. As a group, sell-side analysts anticipate that SpringWorks Therapeutics, Inc. will post -3.17 earnings per share for the current year.

Institutional Investors Weigh In On SpringWorks Therapeutics

Institutional investors have recently modified their holdings of the company. Huntington National Bank raised its stake in SpringWorks Therapeutics by 38.2% during the fourth quarter. Huntington National Bank now owns 694 shares of the company’s stock worth $25,000 after buying an additional 192 shares during the last quarter. AlphaQuest LLC grew its holdings in SpringWorks Therapeutics by 70.2% during the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock worth $36,000 after acquiring an additional 414 shares during the period. Venturi Wealth Management LLC bought a new position in shares of SpringWorks Therapeutics in the 4th quarter worth about $45,000. State of Wyoming lifted its stake in shares of SpringWorks Therapeutics by 39.5% in the 4th quarter. State of Wyoming now owns 1,530 shares of the company’s stock valued at $55,000 after purchasing an additional 433 shares during the period. Finally, GF Fund Management CO. LTD. bought a new stake in shares of SpringWorks Therapeutics during the 4th quarter valued at about $56,000.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on SWTX. HC Wainwright reiterated a “buy” rating and set a $74.00 price objective on shares of SpringWorks Therapeutics in a research report on Wednesday, February 12th. Guggenheim cut their price objective on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Wedbush reaffirmed an “outperform” rating and issued a $81.00 target price on shares of SpringWorks Therapeutics in a report on Thursday. Finally, Evercore ISI lifted their price target on SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $71.50.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.